---
title: Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients
nct_id: NCT05201625
overall_status: UNKNOWN
phase: NA
sponsor: Sohag University
study_type: INTERVENTIONAL
primary_condition: COVID-19
countries: Egypt
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT05201625.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05201625"
ct_last_update_post_date: 2022-01-21
last_seen_at: "2026-05-12T06:48:41.885Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Markers of Severity (CD177,S100A8 &S100A12) in Sever Acute Respiratory Syndrome Coronavirus 2(SARS-COV-2) Patients

**Official Title:** Markers of Severity in Covid 19 Patients

**NCT ID:** [NCT05201625](https://clinicaltrials.gov/study/NCT05201625)

## Key Facts

- **Status:** UNKNOWN
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 90
- **Lead Sponsor:** Sohag University
- **Conditions:** COVID-19
- **Start Date:** 2021-12-15
- **Completion Date:** 2022-12
- **CT.gov Last Update:** 2022-01-21

## Brief Summary

Patients infected with covid-19 have a series of clinical manifestations, including fever, cough, myalgia or fatigue, dyspnea, even acute respiratory distress syndrome (ARDS), acute cardiac injury and secondary infection, and a lot of sever patients had to been admitted to the intensive care unit (ICU)

One of the hallmark of COVID 19 is the cytokine storm that provokes primarily pneumonia followed by systemic inflammation. besides the positive viral nucleic acid analysis and the representative pulmonary CT findings (bilateral distribution of patchy shadows and ground glass opacity), most individual patients showed the changes in several immunological and biological markers . CD177 which is one of the most clinically important neutrophil alloantigen because: i) it is a neutrophil-specific marker representative of neutrophil activation, ii) it was the most highly differentiated expressed gene in patients, and iii) the protein can be measured in the serum, making its use as a marker clinically applicable. It is expressed on neutrophils, neutrophilic metamyelocytes, and myelocytes . Given the contribution of the neutrophil activation pathway in the clustering of COVID-19 patients, neutrophil-activation features that could act as possible reliable markers of disease evolution.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 80 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* COVID 19 hospitalized patients (diagnosed by RT-PCR)

Exclusion Criteria:

* Age below 18 years and above 80.
```

## Arms

- **control group** (ACTIVE_COMPARATOR) — Healthy control group
- **ICU COVID 19 patients** (ACTIVE_COMPARATOR) — ICU COVID 19 patients
- **non-ICU covid 19 patients** (ACTIVE_COMPARATOR) — non-ICU covid 19 patients

## Interventions

- **real time PCR** (DIAGNOSTIC_TEST) — real time PCR

## Primary Outcomes

- **Markers of severity(CD177) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients** _(time frame: one year)_ — \- Measuring gene expression for CD 177 by RT-PCR and also by ELISA.

Measuring gene expression for CD 177 by RT-PCR and also by ELISA.
- **Markers of severity(S100A8&S100A12) in Sever respiratory syndrome coronavirus 2 (SARS-COV-2) patients** _(time frame: one year)_ — Measuring level of S100A8 and S100A12 by ELISA.

## Locations (1)

- Sohag University Hospital, Sohag, Egypt — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.sohag university hospital|sohag||egypt` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT05201625.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT05201625*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*